SG10201608577RA - Salt form of a human hi stone methyltransf erase ezh2 inhibitor - Google Patents
Salt form of a human hi stone methyltransf erase ezh2 inhibitorInfo
- Publication number
- SG10201608577RA SG10201608577RA SG10201608577RA SG10201608577RA SG10201608577RA SG 10201608577R A SG10201608577R A SG 10201608577RA SG 10201608577R A SG10201608577R A SG 10201608577RA SG 10201608577R A SG10201608577R A SG 10201608577RA SG 10201608577R A SG10201608577R A SG 10201608577RA
- Authority
- SG
- Singapore
- Prior art keywords
- stone
- human
- salt form
- ezh2 inhibitor
- methyltransf erase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261624215P | 2012-04-13 | 2012-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201608577RA true SG10201608577RA (en) | 2016-12-29 |
Family
ID=49328166
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912109QA SG10201912109QA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
SG10201608577RA SG10201608577RA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
SG11201406468YA SG11201406468YA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912109QA SG10201912109QA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406468YA SG11201406468YA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
Country Status (25)
Country | Link |
---|---|
US (6) | US9394283B2 (en) |
EP (4) | EP4190777A1 (en) |
JP (3) | JP6255382B2 (en) |
KR (3) | KR102438340B1 (en) |
CN (2) | CN108358899B (en) |
AU (2) | AU2013245878B2 (en) |
BR (1) | BR112014025508B1 (en) |
CA (1) | CA2870005C (en) |
CY (2) | CY1119383T1 (en) |
DK (3) | DK3184523T3 (en) |
ES (3) | ES2745016T3 (en) |
HR (2) | HRP20170295T1 (en) |
HU (3) | HUE045353T2 (en) |
IL (4) | IL282732B2 (en) |
IN (1) | IN2014DN09068A (en) |
LT (2) | LT3184523T (en) |
MX (1) | MX362339B (en) |
NZ (1) | NZ700761A (en) |
PL (3) | PL2836491T3 (en) |
PT (3) | PT2836491T (en) |
RS (2) | RS59392B1 (en) |
RU (1) | RU2658911C2 (en) |
SG (3) | SG10201912109QA (en) |
SI (2) | SI3184523T1 (en) |
WO (1) | WO2013155317A1 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Aryl- or heteroaryl-substituted benzene compounds |
US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CN108358899B (en) * | 2012-04-13 | 2021-07-27 | Epizyme股份有限公司 | Salt forms of human histone methyltransferase EZH2 inhibitor |
CA2870010C (en) | 2012-04-13 | 2023-02-21 | Epizyme, Inc. | Combination therapy for treating cancer |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
NZ706836A (en) | 2012-10-15 | 2019-02-22 | Epizyme Inc | Methods of treating cancer |
US9006242B2 (en) | 2012-10-15 | 2015-04-14 | Epizyme, Inc. | Substituted benzene compounds |
EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2991980B1 (en) | 2013-04-30 | 2019-01-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
JP2016523955A (en) | 2013-07-10 | 2016-08-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッドGlaxosmithkline Intellectual Property No.2 Limited | ZESTE homolog 2 enhancer inhibitor |
WO2015023915A1 (en) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
SG11201602269QA (en) | 2013-10-16 | 2016-04-28 | Epizyme Inc | Hydrochloride salt form for ezh2 inhibition |
AU2014337121A1 (en) * | 2013-10-18 | 2016-04-14 | Epizyme, Inc. | Method of treating cancer |
WO2015077193A1 (en) * | 2013-11-19 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
KR20210117347A (en) | 2013-12-06 | 2021-09-28 | 에피자임, 인코포레이티드 | Combination therapy for treating cancer |
ES2948442T3 (en) | 2014-06-17 | 2023-09-12 | Epizyme Inc | EZH2 inhibitors for the treatment of lymphoma |
HUE043441T2 (en) | 2014-06-20 | 2019-08-28 | Constellation Pharmaceuticals Inc | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
CN106794177A (en) | 2014-10-16 | 2017-05-31 | Epizyme股份有限公司 | The method for the treatment of cancer |
KR102644844B1 (en) * | 2014-11-17 | 2024-03-07 | 에피자임, 인코포레이티드 | Method for treating cancer |
TW201636344A (en) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Inhibitors of EZH2 |
SG10201902664RA (en) | 2015-04-20 | 2019-04-29 | Epizyme Inc | Combination therapy for treating cancer |
MX2017015938A (en) | 2015-06-10 | 2018-11-09 | Epizyme Inc | Ezh2 inhibitors for treating lymphoma. |
IL307260A (en) | 2015-08-24 | 2023-11-01 | Epizyme Inc | Method for treating cancer |
TW201718598A (en) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Inhibitors of EZH2 |
US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
JP2019503391A (en) | 2016-01-29 | 2019-02-07 | エピザイム,インコーポレイティド | Combination therapy to treat cancer |
CA3025933A1 (en) * | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
JP2019521988A (en) | 2016-06-17 | 2019-08-08 | エピザイム,インコーポレイティド | EZH2 inhibitor for treating cancer |
US10457640B2 (en) | 2016-10-19 | 2019-10-29 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of EZH2 |
WO2018137639A1 (en) * | 2017-01-25 | 2018-08-02 | 恩瑞生物医药科技(上海)有限公司 | Histone methyltransferase ezh2 inhibitor, preparation method and pharmaceutical use thereof |
WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
US11602529B2 (en) | 2017-06-02 | 2023-03-14 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
JP7399079B2 (en) | 2017-09-05 | 2023-12-15 | エピザイム,インコーポレイティド | Combination therapy to treat cancer |
WO2020011607A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
KR20220066892A (en) | 2019-08-22 | 2022-05-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | Combination therapy of T cell therapy and Zest homologue 2 enhancer (EH2) inhibitor and related methods |
CA3162315A1 (en) | 2019-12-20 | 2021-06-24 | Marinus Jacobus Verwijs | Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer |
WO2022208552A1 (en) * | 2021-03-31 | 2022-10-06 | Msn Laboratories Private Limited, R&D Center | Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0733729A (en) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Production of n-cyano-n'-substituted-arylcarboxyimidamide compound |
AU694465B2 (en) | 1993-12-27 | 1998-07-23 | Eisai Co. Ltd. | Anthranilic acid derivative |
DE19516776A1 (en) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin regulatory genes |
US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
JP3906935B2 (en) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N-substituted dioxothiazolidylbenzamide derivative and process for producing the same |
CN1332722A (en) | 1998-09-30 | 2002-01-23 | 宝洁公司 | 2-substituted Retoamides |
UA71587C2 (en) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Anthranilic acid amides and use thereof as medicaments |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
DE60139506D1 (en) | 2000-12-28 | 2009-09-17 | Shionogi & Co | 2-PYRIDONE DERIVATIVES WITH AFFINITY FOR THE CANNABINOID TYPE-2 RECEPTOR |
US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
EP2130820A1 (en) | 2002-02-19 | 2009-12-09 | Shionogi & Co., Ltd. | Antipruritics |
TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
JP2007531757A (en) | 2004-03-30 | 2007-11-08 | カイロン コーポレイション | Substituted thiophene derivatives as anticancer agents |
JP5160885B2 (en) | 2004-06-01 | 2013-03-13 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Reconstituted histone methyltransferase complex and method for identifying modulators thereof |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
WO2006130720A2 (en) | 2005-06-02 | 2006-12-07 | University Of North Carolina At Chapel Hill | Purification, characterization and reconstitution of a ubiquitin e3 ligase |
FR2889526B1 (en) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE |
BRPI0618417A2 (en) | 2005-10-19 | 2012-07-31 | Gruenenthal Chemie | new vanillary receptor ligands and their use to produce drugs |
CA2626402C (en) | 2005-10-21 | 2011-02-15 | Merck & Co., Inc. | Potassium channel inhibitors |
EP1941060B1 (en) | 2005-10-28 | 2012-02-29 | The University of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
US8163749B2 (en) | 2005-12-14 | 2012-04-24 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
JP5167149B2 (en) | 2006-01-20 | 2013-03-21 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Leukemia diagnosis and treatment targets |
EP2018166A2 (en) | 2006-05-15 | 2009-01-28 | Irm Llc | Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors |
WO2007136592A2 (en) | 2006-05-18 | 2007-11-29 | Amphora Discovery Corporation | 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents |
EP2086318A4 (en) | 2006-10-10 | 2009-12-23 | Burnham Inst Medical Research | Neuroprotective compositions and methods |
CA2676173A1 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
DE102007017884A1 (en) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Novel vanilloid receptor ligands and their use in the preparation of medicines |
WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
DE102007047737A1 (en) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidine and piperazine derivatives |
WO2009058298A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | P2x3, receptor antagonists for treatment of pain |
KR101665143B1 (en) | 2007-12-19 | 2016-10-11 | 캔써 리서치 테크놀로지 리미티드 | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
US8299093B2 (en) | 2008-08-08 | 2012-10-30 | New York Blood Center, Inc. | Small molecule inhibitors of retroviral assembly and maturation |
FR2934995B1 (en) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | POLYSUBSTITUTED AZETIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF |
WO2010111653A2 (en) | 2009-03-27 | 2010-09-30 | The Uab Research Foundation | Modulating ires-mediated translation |
WO2011011366A2 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
EP2521558A4 (en) | 2009-12-30 | 2013-07-03 | Avon Prod Inc | Topical lightening composition and uses thereof |
UA110112C2 (en) * | 2010-05-07 | 2015-11-25 | Глаксосмітклайн Ллс | Indoles |
ES2528269T3 (en) * | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
JP5864546B2 (en) * | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | Indazole |
EP2614369B1 (en) | 2010-09-10 | 2016-02-03 | Epizyme, Inc. | Method for determining the suitability of inhibitors of human ezh2 in treatment |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2012075080A1 (en) | 2010-12-01 | 2012-06-07 | Glaxosmithkline Llc | Indoles |
KR20130124959A (en) | 2010-12-03 | 2013-11-15 | 에피자임, 인코포레이티드 | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
TWI598336B (en) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | Substituted benzene compounds |
JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Aryl- or heteroaryl-substituted benzene compounds |
HUE042271T2 (en) | 2012-03-12 | 2019-06-28 | Epizyme Inc | Inhibitors of human ezh2, and methods of use thereof |
CA2870010C (en) | 2012-04-13 | 2023-02-21 | Epizyme, Inc. | Combination therapy for treating cancer |
CN108358899B (en) * | 2012-04-13 | 2021-07-27 | Epizyme股份有限公司 | Salt forms of human histone methyltransferase EZH2 inhibitor |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
NZ706836A (en) | 2012-10-15 | 2019-02-22 | Epizyme Inc | Methods of treating cancer |
SG11201602269QA (en) | 2013-10-16 | 2016-04-28 | Epizyme Inc | Hydrochloride salt form for ezh2 inhibition |
-
2013
- 2013-04-11 CN CN201810245662.3A patent/CN108358899B/en active Active
- 2013-04-11 IL IL282732A patent/IL282732B2/en unknown
- 2013-04-11 IN IN9068DEN2014 patent/IN2014DN09068A/en unknown
- 2013-04-11 HU HUE16191716A patent/HUE045353T2/en unknown
- 2013-04-11 JP JP2015505912A patent/JP6255382B2/en active Active
- 2013-04-11 KR KR1020207015664A patent/KR102438340B1/en active IP Right Grant
- 2013-04-11 BR BR112014025508-3A patent/BR112014025508B1/en active IP Right Grant
- 2013-04-11 IL IL296199A patent/IL296199A/en unknown
- 2013-04-11 PL PL13774979T patent/PL2836491T3/en unknown
- 2013-04-11 NZ NZ700761A patent/NZ700761A/en unknown
- 2013-04-11 ES ES16191716T patent/ES2745016T3/en active Active
- 2013-04-11 CA CA2870005A patent/CA2870005C/en active Active
- 2013-04-11 RU RU2014145544A patent/RU2658911C2/en not_active Application Discontinuation
- 2013-04-11 SI SI201331566T patent/SI3184523T1/en unknown
- 2013-04-11 DK DK16191716.6T patent/DK3184523T3/en active
- 2013-04-11 SG SG10201912109QA patent/SG10201912109QA/en unknown
- 2013-04-11 EP EP22200677.7A patent/EP4190777A1/en active Pending
- 2013-04-11 ES ES19180479T patent/ES2931316T3/en active Active
- 2013-04-11 EP EP16191716.6A patent/EP3184523B1/en active Active
- 2013-04-11 EP EP19180479.8A patent/EP3628670B1/en active Active
- 2013-04-11 SG SG10201608577RA patent/SG10201608577RA/en unknown
- 2013-04-11 RS RSP20191175 patent/RS59392B1/en unknown
- 2013-04-11 KR KR1020147030684A patent/KR102120883B1/en active IP Right Grant
- 2013-04-11 WO PCT/US2013/036193 patent/WO2013155317A1/en active Application Filing
- 2013-04-11 PT PT137749792T patent/PT2836491T/en unknown
- 2013-04-11 LT LTEP16191716.6T patent/LT3184523T/en unknown
- 2013-04-11 SG SG11201406468YA patent/SG11201406468YA/en unknown
- 2013-04-11 HU HUE13774979A patent/HUE031976T2/en unknown
- 2013-04-11 PL PL19180479.8T patent/PL3628670T3/en unknown
- 2013-04-11 EP EP13774979.2A patent/EP2836491B1/en active Active
- 2013-04-11 PL PL16191716T patent/PL3184523T3/en unknown
- 2013-04-11 US US14/394,431 patent/US9394283B2/en active Active
- 2013-04-11 AU AU2013245878A patent/AU2013245878B2/en active Active
- 2013-04-11 ES ES13774979.2T patent/ES2617379T3/en active Active
- 2013-04-11 MX MX2014012380A patent/MX362339B/en active IP Right Grant
- 2013-04-11 RS RS20170198A patent/RS55690B1/en unknown
- 2013-04-11 HU HUE19180479A patent/HUE060881T2/en unknown
- 2013-04-11 KR KR1020227029511A patent/KR20220123339A/en not_active Application Discontinuation
- 2013-04-11 DK DK19180479.8T patent/DK3628670T3/en active
- 2013-04-11 LT LTEP13774979.2T patent/LT2836491T/en unknown
- 2013-04-11 SI SI201330551A patent/SI2836491T1/en unknown
- 2013-04-11 PT PT16191716T patent/PT3184523T/en unknown
- 2013-04-11 CN CN201380030902.3A patent/CN104603130B/en active Active
- 2013-04-11 PT PT191804798T patent/PT3628670T/en unknown
- 2013-04-11 DK DK13774979.2T patent/DK2836491T3/en active
-
2014
- 2014-10-07 IL IL235045A patent/IL235045B/en active IP Right Grant
-
2016
- 2016-06-30 US US15/199,522 patent/US9872862B2/en active Active
-
2017
- 2017-02-22 HR HRP20170295TT patent/HRP20170295T1/en unknown
- 2017-03-06 CY CY20171100290T patent/CY1119383T1/en unknown
- 2017-10-12 JP JP2017198642A patent/JP6634058B2/en active Active
- 2017-12-11 US US15/837,390 patent/US10245269B2/en active Active
-
2018
- 2018-01-09 AU AU2018200168A patent/AU2018200168B2/en active Active
- 2018-10-02 JP JP2018187463A patent/JP2018199740A/en active Pending
-
2019
- 2019-02-08 US US16/270,752 patent/US10821113B2/en active Active
- 2019-04-21 IL IL266165A patent/IL266165B/en active IP Right Grant
- 2019-09-13 HR HRP20191653TT patent/HRP20191653T1/en unknown
- 2019-09-18 CY CY20191100981T patent/CY1122883T1/en unknown
-
2020
- 2020-09-25 US US17/032,432 patent/US11491163B2/en active Active
-
2022
- 2022-09-29 US US17/936,555 patent/US20230140327A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282732A (en) | Salt form of a human hi stone methyltransf erase ezh2 inhibitor | |
IL259958B (en) | Heterocyclic inhibitors of glutaminase | |
IL232599A (en) | Hydrobromide salt of pridopidine | |
EP2903613A4 (en) | Inhibitors of irak4 activity | |
EP2903617A4 (en) | Inhibitors of irak4 activity | |
EP2678018A4 (en) | Combination of kanase inhibitors and uses thereof | |
IL270748B (en) | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors | |
EP2760853A4 (en) | Novel salts of alogliptin | |
ZA201401417B (en) | Novel soft rock inhibitors | |
PL2709584T3 (en) | Sensory use of 6-cyclopentylidenehexane derivatives | |
ZA201205358B (en) | Use of a salt of bistetrazolylamine | |
ZA201308872B (en) | Use of a dinitromethane salt |